IP Library Granted Patent US 8,460,671
Granted Patent B2
US 8,460,671 · App. 13/215,841 · Granted Jun 11, 2013

Compositions and methods for the therapy and diagnosis of influenza

Inventors: Andres Grandea, III (Shoreline, WA); Gordon King (Shoreline, WA); Thomas Cox (Redmond, WA); Ole Olsen (Everett, WA); Jennifer Mitcham (Redmond, WA); Matthew Moyle (Redmond, WA)
Assignee: Theraclone Sciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,460,671
App. No.
13/215,841
Granted
Jun 11, 2013
Kind
B2
Abstract

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Claims (3)

1. A method for the treatment of an influenza A virus infection in a subject, comprising administering to the subject a composition comprising an isolated anti-matrix 2 ectodomain (M2e) antibody, wherein the M2e is of an influenza A virus, and wherein the antibody comprises,

a) a V H CDR1 region comprising the amino acid sequence of NYYWS (SEQ ID NO: 72); a V H CDR2 region comprising the amino acid sequence of FIYYGGNTKYNPSLKS (SEQ ID NO: 74); a V H CDR3 region comprising the amino acid sequence of ASCSGGYCILD (SEQ ID NO: 76); a V L CDR1 region comprising the amino acid sequence of RASQNIYKYLN (SEQ ID NO: 59); a V L CDR2 region comprising the amino acid sequence of AASGLQS (SEQ ID NO: 61); a V L CDR3 region comprising the amino acid sequence of and QQSYSPPLT (SEQ ID NO: 63), or

b) a V H CDR1 region comprising the amino acid sequence of SNYMS (SEQ ID NO: 103); a V H CDR2 region comprising the amino acid sequence of VIYSGGSTYYADSVK (SEQ ID NO: 105), a V H CDR3 region comprising the amino acid sequence of CLSRMRGYGLDV (SEQ ID NO: 107); a V L CDR1 region comprising the amino acid sequence of RTSQSISSYLN (SEQ ID NO: 92); a V L CDR2 region comprising the amino acid sequence of AASSLQSGVPSRF (SEQ ID NO: 94); and a V L CDR3 region comprising the amino acid sequence of QQSYSMPA (SEQ ID NO: 96).

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Dec 29, 2015
From: MIDCAP FINANCIAL TRUST, AS AGENT FOR LENDERS
To: THERACLONE SCIENCES, INC.
Reel/Frame 037396/0957 →
SECURITY INTEREST Recorded Nov 19, 2015
From: THERACLONE SCIENCES, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 037146/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2011
From: GRANDEA, ANDRES G., III; KING, GORDON; COX, THOMAS; OLSEN, OLE; MITCHAM, JENNIFER
To: SPALTUDAQ CORPORATION
Reel/Frame 027169/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2011
From: MOYLE, MATTHEW
To: SPALTUDAQ CORPORATION
Reel/Frame 027169/0095 →
CHANGE OF NAME Recorded Nov 3, 2011
From: SPALTUDAQ CORPORATION
To: THERACLONE SCIENCES, INC.
Reel/Frame 027172/0702 →
Continuity (6)
Continuation 12269781 · Nov 12, 2008
Provisional Application 60987353 · Nov 12, 2007
Provisional Application 60987355 · Nov 12, 2007
Provisional Application 61053840 · May 16, 2008
Provisional Application 61095208 · Sep 8, 2008
Related Publication 20120171218A1 · Jul 5, 2012